J. Kennedy

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.

D. Cruickshank, S. M. Crawford, S. Kaye, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

D. Cruickshank, S. M. Crawford, S. Kaye, 1992, The Lancet.

A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer.

S. Kaye, M. Harding, A. Maclean, 1988, British Journal of Cancer.

Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment.

S. Kaye, A. Belfield, D. Pledger, 1988, European journal of cancer & clinical oncology.

Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer

K. O'Byrne, J. Reynolds, D. Hollywood, 2007, Annals of surgery.

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

R. Sullivan, Y. Najjar, Douglas B. Johnson, 2020, Journal for immunotherapy of cancer.

Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer.

J. Reynolds, D. Hollywood, E. Mulligan, 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Clinical decision aids in colon cancer: a comparison of two predictive nomograms.

F. Kelleher, M. Collins, I. Collins, 2012, Clinical colorectal cancer.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide, adriamycin and cis‐platinum

K. Calman, D. Cunningham, S. Kaye, 1984, British journal of obstetrics and gynaecology.

Prognostic factor analysis, for patients with no evidence of disease after initial chemotherapy for advanced epithelial ovarian carcinoma

W. Fullerton, A. Maclean, J. Davis, 1995, International Journal of Gynecologic Cancer.